A Novel & Tailorable Topical Wound Therapy Based on a Semi-Interpenetrating Polym

一本小说

• 批准号: 7275122
• 负责人: DAVID J VACHON
• 金额: $ 14.13万
• 依托单位: IASIS MOLECULAR SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7275122
• 关键词: Novel; Tailorable; Topical; Wound; Therapy

DESCRIPTION (provided by applicant): Abstract A water-soluble, inexpensive, and biocompatible polymer with unique properties and processing characteristics has been proven effective against multiple serine and metalloproteases in testing. The polymer is used to formulate wound therapies that offer an alternative to existing costly products. The major specific aim(s) of this work detail the formulation and animal evaluation of a hydrogel dressing that releases the water-soluble polymer agent in order to control the proteolytic environment of a chronic wound as well as deliver a secondary agent such as an anti-oxidant. This simple and rational therapy is based upon the idea that controlling proteolysis in a chronic wound environment could result in a more favorable healing environment. The polymer technology described herein may have application beyond wound therapies where controlling proteases and delivering a secondary agent simultaneously may be beneficial. Conservative estimates suggest that over 2 million people annually in the U.S. suffer from chronic ulcers (Rees et. al., 1999) and these numbers are expected to increase in view of the aging population and the rise of diabetes. The prevalence of diabetes for all age-groups worldwide has been estimated to be 2.8% in 2000 and will rise to 4.4% in 2030. Accordingly, the total number of people with diabetes is projected to approach 366 million in 2030. Among persons diagnosed as having diabetes mellitus, the prevalence of foot ulcers is 4% to 10%, the annual population-based incidence is 1.0% to 4.1%, and the lifetime incidence may be as high as 25%. In addition, the incidence of ulcer recurrence after complete healing approaches 30% within 12 months. Diabetic foot ulcers cause substantial emotional, physical, productivity, and financial losses. The estimated cost of treating a diabetic foot ulcer in 1999 was $18,000. In instances requiring amputation, these costs jumped to $28 000. These estimates do not take into account the personal and socioeconomic impact of these wounds on a patient's life. A wound treatment that utilizes a commercially available & inexpensive, water- soluble polymer of tailorable utility that leverages our fundamental understanding of the underlying biology and biochemistry of chronic wounds in order to provide a multifaceted treatment is the subject of our investigation. The water-soluble polymer will be formulated into a dressing of three derivative forms that will be evaluated for their capacities to control the levels of certain damaging wound proteases via inhibition, and affect the wound by additionally delivering an NO donor, an NO precursor, or an antioxidant to the wound site.

描述（由申请人提供）：摘要一种具有独特性质和加工特性的水溶性、廉价且生物相容性聚合物已在测试中被证明可有效对抗多种丝氨酸和金属蛋白酶。该聚合物用于配制伤口疗法，为现有昂贵产品提供替代品。这项工作的主要具体目标详细介绍了水凝胶敷料的配方和动物评估，该敷料释放水溶性聚合物剂，以控制慢性伤口的蛋白水解环境，并提供辅助剂，例如抗氧化剂。 -氧化剂。这种简单而合理的疗法基于这样的想法：控制慢性伤口环境中的蛋白水解可以产生更有利的愈合环境。本文描述的聚合物技术可以具有超出伤口治疗的应用，在伤口治疗中同时控制蛋白酶和递送第二药剂可能是有益的。保守估计表明，美国每年有超过 200 万人患有慢性溃疡（Rees 等，1999），并且鉴于人口老龄化和糖尿病的增加，预计这些数字还会增加。据估计，2000 年全球所有年龄段的糖尿病患病率为 2.8%，到 2030 年将上升至 4.4%。因此，预计 2030 年糖尿病患者总数将接近 3.66 亿。患有糖尿病的人，足部溃疡的患病率为 4% 至 10%，人群年发病率为 1.0% 至 4.1%，终生发生率可能高达25%。此外，完全愈合后12个月内溃疡复发率接近30%。糖尿病足溃疡会造成巨大的情感、身体、生产力和经济损失。 1999 年治疗糖尿病足溃疡的估计费用为 18,000 美元。在需要截肢的情况下，这些费用跃升至 28,000 美元。这些估计并未考虑这些伤口对患者生活的个人和社会经济影响。我们研究的主题是利用市售且廉价的可定制用途的水溶性聚合物进行伤口治疗，利用我们对慢性伤口的基础生物学和生物化学的基本理解，以提供多方面的治疗。水溶性聚合物将被配制成三种衍生形式的敷料，将评估它们通过抑制控制某些破坏性伤口蛋白酶水平的能力，并通过另外递送NO供体、NO前体或影响伤口来影响伤口。伤口部位的抗氧化剂。